信達生物製藥

INNOVENT BIOLOGICS, INC.

(Incorporated in the Cayman Islands with Limited Liability)

(Stock Code: 1801)

VOLUNTARY ANNOUNCEMENT
INNOVENT ENTERED A STRATEGIC COLLABORATION AGREEMENT WITH MD ANDERSON CANCER CENTER TO CO-DEVELOP PD-1 INHIBITOR TYVYT® (SINTILIMAB INJECTION) IN RARE CANCERS

This announcement is made by Innovent Biologics, Inc. (the "**Company**" or "**Innovent**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board of directors of the Company (the "**Board**") is pleased to announce that the Company entered into a strategic collaboration agreement (the "**Agreement**") with The University of Texas MD Anderson Cancer Center ("**MD Anderson**") to co-develop TYVYT® (sintilimab injection), an innovative anti-PD-1 monoclonal antibody, in rare cancers in the United States (the "**U.S.**"). This co-development will be enabled by MD Anderson's unique experience in conducting clinical trials for even the rarest cancers not often seen by other centers. These studies will provide opportunities for the Company to pursue approval of sintilimab by the U.S. Food and Drug Administration for multiple rare cancer indications. In addition, the Company is also independently pursuing for approval of sintilimab for larger cancer indications. The introduction of sintilimab to the U.S. will broaden the treatment options available to patients with rare cancer types, many of whom do not currently have an effective standard of care.

Under the Agreement, the Company and MD Anderson will co-fund the development activities for sintilimab, which may include multiple clinical research studies to be conducted by MD Anderson.

ABOUT TYVYT® (SINTILIMAB INJECTION)

TYVYT® (sintilimab injection), an innovative drug jointly developed in China by the Group and Eli Lilly and Company with global quality standards, has been granted marketing approval by the National Medical Products Administration (the "**NMPA**") for treatment of relapsed or refractory classic Hodgkin's lymphoma after second-line or later systemic chemotherapy, and included in the 2019 Guidelines of Chinese Society of Clinical Oncology for Lymphoid Malignancies. TYVYT® (sintilimab injection) is the only PD-1 inhibitor that has been included in the new Catalogue of the National Reimbursement Drug List since November 2019. In April 2020, the NMPA accepted the supplemental new drug application for TYVYT in combination with ALIMTA® (pemetrexed) and platinum chemotherapy as first-line therapy in non-squamous non-small cell lung cancer ("**NSCLC**"). In May 2020, TYVYT combined with Gemzar® (gemcitabine for injection) and platinum chemotherapy met the predefined primary endpoint in the Phase 3 ORIENT-12 study as first-line therapy in patients with squamous NSCLC, TYVYT monotherapy met the primary endpoint in the ORIENT-2 study as second-line therapy in patients with advanced or metastatic esophageal squamous cell carcinoma as well.

TYVYT® (sintilimab injection) is a type of immunoglobulin G4 monoclonal antibody, which specifically binds to PD-1 molecules on the surface of T-cells, and blocks the PD-1/PD-Ligand 1 (Programmed Death-Ligand 1, PD-L1) pathway leading to tumor immune tolerance and reactivates T-cells to kill cancer cells. The Company is currently conducting more than 20 clinical studies with sintilimab to evaluate its safety and efficacy in a wide variety of cancer indications, including more than 10 registration or pivotal clinical trials.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited: We cannot guarantee that we will be able to develop or ultimately market sintilimab successfully in the U.S.. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By Order of the Board
Innovent Biologics, Inc.
Dr. De-Chao Michael Yu
Chairman and Executive Director

Hong Kong, China, May 19, 2020

As at the date of this announcement, the Board comprises Dr. De-Chao Michael Yu as Chairman and Executive Director and Mr. Ronald Hao Xi Ede as Executive Director, Mr. Shuyun Chen as Non-executive Director, and Dr. Charles Leland Cooney, Ms. Joyce I-Yin Hsu and Dr. Kaixian Chen as Independent Non-executive Directors.